Taiwan Health and Bio DataBank Technology Delegation Visits Bestat to Explore AI and Health Data Synergy
Taiwan Health and Bio DataBank Technology INC., led by Chairman Dr. Kung-Yee Liang, visited Bestat Pharmaservices today to explore potential collaboration in the fields of AI applications and health data. The meeting was personally hosted by Bestat's CEO, Samuel Su, highlighting the high level of importance both parties place on cross-disciplinary innovation.
Dr. Kung-Yee Liang is a preeminent biostatistician and educator in Taiwan. Having served as the President of the National Health Research Institutes (NHRI), President of National Yang-Ming University, and an Academician of Academia Sinica, Dr. Liang has dedicated his career to advancing Taiwan's biomedical technology and health data infrastructure. This visit aims to combine Bestat's professional strengths in statistical analysis and clinical trials to explore the transformative possibilities of integrating AI with health data.
As both Dr. Liang and Samuel share deep academic backgrounds in biostatistics, the in-depth dialogue between them on specialized technical topics was both highly engaging and constructive, establishing a solid foundation for future strategic partnership.
This exchange also aligns with the United Nations Sustainable Development Goals (SDGs), specifically SDG 3: Good Health and Well-being and SDG 9: Industry, Innovation, and Infrastructure. By optimizing data analysis techniques, we can effectively accelerate the development of new drugs and precision medicine. Furthermore, this dialogue echoes SDG 17: Partnerships for the Goals, demonstrating a shared commitment to building a robust biomedical digital ecosystem.
Moving forward, Bestat aims to evolve beyond being a guardian of data to becoming a catalyst for data value. By partnering with professional organizations like Taiwan Health and Bio DataBank Technology, we aspire to translate biomedical big data into meaningful clinical insights, ushering in a new era of AI-assisted R&D and contributing indispensable momentum to the global precision medicine industry.
Taiwan Health and Bio DataBank Technology INC., led by Chairman Dr. Kung-Yee Liang, visited Bestat Pharmaservices today to explore potential collaboration in the fields of AI applications and health data. The meeting was personally hosted by Bestat's CEO, Samuel Su, highlighting the high level of importance both parties place on cross-disciplinary innovation.
Dr. Kung-Yee Liang is a preeminent biostatistician and educator in Taiwan. Having served as the President of the National Health Research Institutes (NHRI), President of National Yang-Ming University, and an Academician of Academia Sinica, Dr. Liang has dedicated his career to advancing Taiwan's biomedical technology and health data infrastructure. This visit aims to combine Bestat's professional strengths in statistical analysis and clinical trials to explore the transformative possibilities of integrating AI with health data.
As both Dr. Liang and Samuel share deep academic backgrounds in biostatistics, the in-depth dialogue between them on specialized technical topics was both highly engaging and constructive, establishing a solid foundation for future strategic partnership.
This exchange also aligns with the United Nations Sustainable Development Goals (SDGs), specifically SDG 3: Good Health and Well-being and SDG 9: Industry, Innovation, and Infrastructure. By optimizing data analysis techniques, we can effectively accelerate the development of new drugs and precision medicine. Furthermore, this dialogue echoes SDG 17: Partnerships for the Goals, demonstrating a shared commitment to building a robust biomedical digital ecosystem.
Moving forward, Bestat aims to evolve beyond being a guardian of data to becoming a catalyst for data value. By partnering with professional organizations like Taiwan Health and Bio DataBank Technology, we aspire to translate biomedical big data into meaningful clinical insights, ushering in a new era of AI-assisted R&D and contributing indispensable momentum to the global precision medicine industry.